[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337750-105":59,"doc-detail-337750-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","safety-and-biological-outcomes-following-a-phase-1-trial-of-gd2-specific-car-t-cells-in-patients-with-gd2-positive-metastatic-melanoma-and-other-solid-cancers","Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers","","Phase 1 clinical trial evaluating third-generation GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid tumors. The study assessed feasibility and safety, including CAR-T immune persistence and detailed immune profiling via multiplex cytokine arrays and immune phenotyping of original, circulating, and selected tumor-infiltrating CAR-T cells. Results show point-of-care CAR-T manufacturing feasibility and tolerability with no dose-limiting toxicities or severe adverse events, with immune phenotype changes and limited clinical effect.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/safety-and-biological-outcomes-following-a-phase-1-trial-of-gd2-specific-car-t-cells-in-patients-with-gd2-positive-metastatic-melanoma-and-other-solid-cancers/337750/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/safety-and-biological-outcomes-following-a-phase-1-trial-of-gd2-specific-car-t-cells-in-patients-with-gd2-positive-metastatic-melanoma-and-other-solid-cancers/337750.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of the phase 1 trial of GD2-specific CAR-T cells?","Question",{"text":112,"@type":113},"To evaluate feasibility and safety of third-generation GD2-specific CAR-T therapy and to study persistence and immune outcomes in patients with GD2-positive metastatic melanoma and other solid cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was GD2-CAR-T therapy administered in this study?",{"text":117,"@type":113},"It was tested in combination with BRAF/MEK inhibitor therapy in metastatic melanoma patients, and as monotherapy in colorectal cancer and fibromyxoid sarcoma patients.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key safety and feasibility findings?",{"text":121,"@type":113},"Point-of-care manufacturing of CAR-T products was feasible, and a single intravenous infusion was well tolerated with no dose-limiting toxicities or severe adverse events.",{"name":123,"@type":110,"acceptedAnswer":124},"Did the therapy show clinical and immune activity?",{"text":125,"@type":113},"The study reported immune activity and improvements in CAR-T immune phenotype and expansion after a modified manufacturing procedure, but clinical effect was limited.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},337750,1790194857,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Open access Original research  \nTo cite: Gargett T, Truong NTH, Gardam B, et al. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells inpatients with GD2-positive metastatic melanoma and other solid cancers. Journal for ImmunoTherapy of Cancer 2024;12:e008659 . doi:10 . 1136/ jitc-2023-008659  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2023-008659](jitc-2023-008659)) .  \nAccepted 28 April 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. For numbered affiliations see end of article.  \nCorrespondence to  \nDr Tessa Gargett;  \n[tessa.gargett@sa.gov.au](tessa.gargett@sa.gov.au)  \nSafety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers  \nTessa Gargett  ,1,2,3 Nga T H Truong,1,3 Bryan Gardam,1,2 Wenbo Yu,1,3 Lisa M Ebert  ,1,2,3 Amy Johnson,4 Erica C F Yeo,1 Nicole L Wittwer  ,1,3 Gonzalo Tapia Rico,2,3 Jesikah Logan,3 Purany Sivaloganathan,3 Maria Collis,5 Andrew Ruszkiewicz,2,5,6 Michael P Brown  1,2,3  \nABSTRACT  \nBackground Chimeric antigen receptor (CAR) T cell therapies specific for the CD19 and B-cell maturation antigen have become an approved standard of care worldwide for relapsed and refractory B-cell malignancies. If CAR-T cell therapy for non-hematological malignancies is to achieve the same stage of clinical development, then iterative early-phase clinical testing can add value to the clinical development process for evaluating CAR-T cell products containing different CAR designs and manufactured under differing conditions.  \nMethods We conducted a phase 1 trial of third-generation GD2-specific CAR-T cell therapy, which has previously been tested in neuroblastoma patients. In this study, the GD2-CAR-T therapy was evaluated for the first time in metastatic melanoma patients in combination with BRAF/ MEK inhibitor therapy, and as a monotherapy in patients with colorectal cancer and a patient with fibromyxoid sarcoma. Feasibility and safety were determined and persistence studies, multiplex cytokine arrays on  \nsera and detailed immune phenotyping of the original CAR-T products, the circulating CAR-T cells, and, in select patients, the tumor-infiltrating CAR-T cells were performed.  \nResults We demonstrate the feasibility of manufacturing CAR-T products at point of care for patients with solid cancer and show that a single intravenous infusion was well tolerated with no dose-limiting toxicities or severe adverse events. In addition, we note significant improvements in CAR-T cell immune phenotype, and expansion when a modified manufacturing procedure was adopted for the latter 6 patients recruited to this 12-patient trial. We also show evidence of CAR-T cell-mediated immune activity and in some patients expanded subsets of circulating myeloid cells after CAR-T cell therapy. Conclusions This is the first report of third-generation GD2-targeting CAR-T cells in patients with metastatic melanoma and other solid cancers such as colorectal cancer, showing feasibility, safety and immune activity, but limited clinical effect.  \nTrial registration number ACTRN12613000198729 .  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ GD2 is a clinically validated cancer immunotherapy target antigen and chimeric antigen receptor (CAR) T cell-targeting of GD2 has shown clinically significant activity in neuroblastoma and diffuse midline glioma patients. GD2 is also widely expressed in other neuroectodermal tumors, sarcomas, and lung tumors but associated clinical data and knowledge offactors constraining GD2-CAR-T cell expansion and persistence in patients with solid cancer are limited.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This is the first report of GD2-CAR-T cell therapy in patients with metastatic colorectal cancer and ad","cbCaiuX7XDHbvifQ","https://ap.wps.com/l/cbCaiuX7XDHbvifQ","pdf",21433335,17,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n## Trial registration","[{\"question\":\"What was the purpose of the phase 1 trial of GD2-specific CAR-T cells?\",\"answer\":\"To evaluate feasibility and safety of third-generation GD2-specific CAR-T therapy and to study persistence and immune outcomes in patients with GD2-positive metastatic melanoma and other solid cancers.\"},{\"question\":\"How was GD2-CAR-T therapy administered in this study?\",\"answer\":\"It was tested in combination with BRAF/MEK inhibitor therapy in metastatic melanoma patients, and as monotherapy in colorectal cancer and fibromyxoid sarcoma patients.\"},{\"question\":\"What were the key safety and feasibility findings?\",\"answer\":\"Point-of-care manufacturing of CAR-T products was feasible, and a single intravenous infusion was well tolerated with no dose-limiting toxicities or severe adverse events.\"},{\"question\":\"Did the therapy show clinical and immune activity?\",\"answer\":\"The study reported immune activity and improvements in CAR-T immune phenotype and expansion after a modified manufacturing procedure, but clinical effect was limited.\"}]","Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers | PDF",1790020483,43,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b867720445bbe01582dd58a1d953a748.webp",983,1310,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b74abaea69c923fc981ce279ac8a261.webp",982,1309,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5812920f47e61e7e873936063bc8b13.webp",981,1308,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee204f13014432c9e86587bd097fcc49.webp",980,1306]